Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII

Human coagulation factor VIII (FVIII) is a key co-factor in the clotting cascade, the deficiency of which leads to Hemophilia A. Human plasma-derived (pdFVIII) and recombinant FVIII (rFVIII) had been used as effective products to prevent and treat bleeding episodes. Both FVIII products share identical amino acid sequences and appear to be equivalent as of clinical efficiency. However, systemic reviews found an increased risk of neutralizing antibody (or inhibitor) development with recombinant products. FVIII is a highly glycosylated protein, and its glycosylation pattern is specific to host cells and environments. The roles of glycosylation in immune responses toward pdFVIII and rFVIII are yet to be defined. Herein, we systemically profiled N- and O-glycomes of pdFVIII and rFVIII using a mass spectrometry-based glycoproteomic strategy. A total of 110 site-specific N-glycopeptides consisting of 61 N-glycoforms were identified quantitatively from rFVIII and pdFVIII. Additionally, 31 O-glycoforms were identified on 23 peptides from rFVIII and pdFVIII. A comprehensive comparison of their site-specific glycan profiles revealed distinct differences between the glycosylation of pdFVIII and rFVIII.

[1]  M. Cormier,et al.  Advances in knowledge of inhibitor formation in severe haemophilia A , 2020, British journal of haematology.

[2]  Z. Sauna,et al.  Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. , 2019, Blood advances.

[3]  S. Garger,et al.  Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products , 2019, Drug design, development and therapy.

[4]  S. Ng,et al.  Impact of host cell line choice on glycan profile , 2018, Critical reviews in biotechnology.

[5]  J. Dennis,et al.  N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice , 2018, Haematologica.

[6]  B. Reipert,et al.  In‐depth comparison of N‐glycosylation of human plasma‐derived factor VIII and different recombinant products: from structure to clinical implications , 2018, Journal of thrombosis and haemostasis : JTH.

[7]  Keith S Wilson,et al.  Carbohydrate structure: the rocky road to automation. , 2017, Current opinion in structural biology.

[8]  T. Biedermann,et al.  Alpha‐gal is a possible target of IgE‐mediated reactivity to antivenom , 2017, Allergy.

[9]  Adnan Halim,et al.  Characterizing the O-glycosylation landscape of human plasma, platelets, and endothelial cells. , 2017, Blood advances.

[10]  Bin Zhang,et al.  Characterization of Missense Mutations in Factor VIII That Lead to Abnormal N-Linked Glycosylation , 2016 .

[11]  V. Ramanan,et al.  A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. , 2016, The New England journal of medicine.

[12]  Chen Chen,et al.  Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs. , 2016, Drug discovery today.

[13]  Y. Katterle,et al.  BAY 81‐8973, a full‐length recombinant factor VIII: results from an International comparative laboratory field study , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  Wolfgang Friess,et al.  N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  P. Wang,et al.  A precise approach in large scale core-fucosylated glycoprotein identification with low- and high-normalized collision energy. , 2015, Journal of proteomics.

[16]  Cheng Chang,et al.  N‐linked glycoproteome profiling of human serum using tandem enrichment and multiple fraction concatenation , 2013, Electrophoresis.

[17]  D. Green.  Factor VIII inhibitors: a 50‐year perspective , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  P. Bondarenko,et al.  High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. , 2011, Glycobiology.

[19]  S. Mohammed,et al.  Improved peptide identification by targeted fragmentation using CID, HCD and ETD on an LTQ-Orbitrap Velos. , 2011, Journal of proteome research.

[20]  A. Varki,et al.  Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins , 2010, Nature Biotechnology.

[21]  L. Thim,et al.  Purification and characterization of a new recombinant factor VIII (N8) , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  Matthias Mann,et al.  Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. , 2009, Journal of proteome research.

[23]  M. Othman,et al.  Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. , 2009, Blood.

[24]  Kai Griebenow,et al.  Effects of glycosylation on the stability of protein pharmaceuticals. , 2009, Journal of pharmaceutical sciences.

[25]  M. Satoh,et al.  Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC , 2008, Drug design, development and therapy.

[26]  Alessio Ceroni,et al.  GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. , 2008, Journal of proteome research.

[27]  S. Kaveri,et al.  A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes , 2007, Proceedings of the National Academy of Sciences.

[28]  S. Kaveri,et al.  VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. , 2007, Blood.

[29]  A. Thompson.  Structure and Function of the Factor VIII Gene and Protein , 2003, Seminars in thrombosis and hemostasis.

[30]  J Bayry,et al.  Pathophysiology of inhibitors to factor VIII in patients with haemophilia A , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[31]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.

[32]  F. Castellino,et al.  Glycosylation of Pichia pastoris ‐derived proteins , 1999, Biotechnology and applied biochemistry.

[33]  A. Burlingame,et al.  Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry. , 1997, Analytical chemistry.

[34]  A. Kobata,et al.  Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. , 1992, The Journal of biological chemistry.

[35]  F. Rosendaal,et al.  The Increasing Prevalence of Haemophilia , 1990, Thrombosis and Haemostasis.

[36]  K Bock,et al.  The Complex Carbohydrate Structure Database. , 1989, Trends in biochemical sciences.

[37]  S. Chavin.  Factor VIII: Structure and function in blood clotting , 2006 .

[38]  M. Ramström,et al.  Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. , 2013, Thrombosis Research.

[39]  Amos Bairoch,et al.  Detailed peptide characterization using PEPTIDEMASS – a World‐Wide‐Web‐accessible tool , 1997, Electrophoresis.

[40]  J. Sixma,et al.  The physiology and pathophysiology of the factor VIII complex. , 1986, Critical reviews in oncology/hematology.